MedElevator
Войти в исследования Orbit (Amsterdam, Netherlands) · 2026
Periocular surgery risk after glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahuja Abhimanyu S, Paredes Alfredo A, Young Benjamin K, Ashraf Davin C
Аннотация
PURPOSE: To evaluate the association between GLP-1RA therapy and the hazard of involutional periocular surgical procedures among patients with type 2 diabetes.
METHODS: This retrospective cohort study used the TriNetX electronic health record database. Adults aged 45 years and older with type 2 diabetes were included. A GLP-1RA cohort was created with evidence of continued therapy defined by a second prescription at least 1 year after initiation. The comparison cohort included patients prescribed other antidiabetic medications, excluding GLP-1RAs. Propensity score matching balanced demographics, comorbidities, and insulin use. The primary outcomes were the hazards of periocular surgery during four nonoverlapping 9-month intervals (0-9, 9-18, 18-27, and 27-36 months) and cumulatively over 0-36 months.
RESULTS: GLP-1RA use was associated with a higher hazard of upper eyelid blepharoplasty (HR range: 1.988-2.788), blepharoptosis repair (HR range: 1.322-1.813), and brow ptosis repair (HR range: 1.683-2.393) compared with other antidiabetic medications (all p ≤ 0.028). Elevated hazard occurred within 0-9 months of treatment and generally increased through 18-27 months.
CONCLUSIONS: GLP-1RA therapy was associated with an increased hazard of involutional periocular surgical procedures compared with other antidiabetic medications, suggesting a potential association between GLP-1RA use and periocular soft tissue changes.
METHODS: This retrospective cohort study used the TriNetX electronic health record database. Adults aged 45 years and older with type 2 diabetes were included. A GLP-1RA cohort was created with evidence of continued therapy defined by a second prescription at least 1 year after initiation. The comparison cohort included patients prescribed other antidiabetic medications, excluding GLP-1RAs. Propensity score matching balanced demographics, comorbidities, and insulin use. The primary outcomes were the hazards of periocular surgery during four nonoverlapping 9-month intervals (0-9, 9-18, 18-27, and 27-36 months) and cumulatively over 0-36 months.
RESULTS: GLP-1RA use was associated with a higher hazard of upper eyelid blepharoplasty (HR range: 1.988-2.788), blepharoptosis repair (HR range: 1.322-1.813), and brow ptosis repair (HR range: 1.683-2.393) compared with other antidiabetic medications (all p ≤ 0.028). Elevated hazard occurred within 0-9 months of treatment and generally increased through 18-27 months.
CONCLUSIONS: GLP-1RA therapy was associated with an increased hazard of involutional periocular surgical procedures compared with other antidiabetic medications, suggesting a potential association between GLP-1RA use and periocular soft tissue changes.